There are several sets of guidelines for the treatment of infective endocarditis, reflecting the need for differing treatment in various countries and times. This review considers the need for differing treatment modalities and in particular the utility of the glycopeptide antibiotics vancomycin and teicoplanin. Specific recommendations are offered as to when to consider the use of glycopeptides, appropriate dosage, length of treatment course and whether to use monotherapy or combined therapy. Used judiciously, the glycopeptides give results as good as can be achieved with other antimicrobial agents without exceptional toxicity. The potential of teicoplanin for use in the outpatient treatment of infective endocarditis is considered. (C) 199...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
The frequency of infective endocarditis (IE) has increased 3 times over the past 30 years. The incid...
Abstract Background The role of oral antibiotic thera...
There are several sets of guidelines for the treatment of infective endocarditis, reflecting the nee...
BACKGROUND: Despite the number of antibacterial agents currently available, endocarditis remains a d...
Glycopeptides have been recommended as therapy for endocarditis. MICs and MBCs of vancomycin and tei...
Infective endocarditis is an uncommon disease but retains a high mortality. Glycopeptides are used f...
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is increasing. V...
It would be difficult to envision the practice of infectious diseases over the past 20 years without...
The glycopeptide antibacterial drugs vancomycin and teicoplanin are widely used in hospitals for the...
Vancomycin and teicoplanin are the two glycopeptides currently used in the clinics for the treatment...
Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usu...
Infective endocarditis (IE), despite the diagnostic and therapeutic advances, still remains a seriou...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
The present paper completes a series of papers on the current aspects of infective endocarditis (IE)...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
The frequency of infective endocarditis (IE) has increased 3 times over the past 30 years. The incid...
Abstract Background The role of oral antibiotic thera...
There are several sets of guidelines for the treatment of infective endocarditis, reflecting the nee...
BACKGROUND: Despite the number of antibacterial agents currently available, endocarditis remains a d...
Glycopeptides have been recommended as therapy for endocarditis. MICs and MBCs of vancomycin and tei...
Infective endocarditis is an uncommon disease but retains a high mortality. Glycopeptides are used f...
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is increasing. V...
It would be difficult to envision the practice of infectious diseases over the past 20 years without...
The glycopeptide antibacterial drugs vancomycin and teicoplanin are widely used in hospitals for the...
Vancomycin and teicoplanin are the two glycopeptides currently used in the clinics for the treatment...
Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usu...
Infective endocarditis (IE), despite the diagnostic and therapeutic advances, still remains a seriou...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
The present paper completes a series of papers on the current aspects of infective endocarditis (IE)...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
The frequency of infective endocarditis (IE) has increased 3 times over the past 30 years. The incid...
Abstract Background The role of oral antibiotic thera...